Ya... Lau sai this week again for gloves counter. All monies into banks and genting. ridiculous considering it is still shit earnings and back to normal is more than 1 year away. Bottom fishing the gloves counter. Add more again
Every country is stocking glove by knowing it is a long way to go. Pandemic is not going to stop, one ended and another is resurface. This is the world now.
just my own opinion, the NP of next few Qs will around RM40mil to RM50 mil at least, at current price the PE only about 14 times & i thk a healthy glove company average PE shall be around 24 to 28 times. TP RM6.50 to RM7 not a dream.
Covid-19 vaccine dampens sentiment on glove counters in morning trade KUALA LUMPUR (Nov 16): Glove stocks were headed lower in Bursa Malaysia's morning trading session today due to the news flow of Covid-19 vaccine progress, which dampened sentiment on the counters. As at the time of writing, glove stocks were among the top losers today. At 11.53am, Hartalega Holdings Bhd, being the second top loser, was down 4.29% or 66 sen at RM14.72, bringing its market capitalisation lower to RM50.54 billion. It saw some 2.78 million shares traded. In the fourth place was Supermax Corp Bhd, which fell 5.24% or 46 sen to RM8.32, with a market value of RM22.72 billion. More than seven months after the World Health Organization (WHO) declared the Covid-19 outbreak in China a “public health emergency of international concern”, the global economy continues to reel from the impact of the virus. Meanwhile, Top Glove Corp Bhd, which bought back 8.94 million or 0.72% of its shares for RM69.9 million in the open market last Friday, dropped 3.98% or 31 sen to RM7.47, valuing the stock at RM61.47 billion. The counter was the seventh biggest loser as at the time of writing. The smaller players were also not spared from the selling pressure. Kossan Rubber Industries Bhd lost 4.2% or 28 sen to RM6.38, Careplus Group Bhd fell 6.58% or 20 sen to RM2.84, and Comfort Gloves Bhd shed 4.71% or 19 sen to RM3.84. The Healthcare Index was dragged down by the glove stocks, declining by 1.75% or 69.68 points to 3,921.47. Last week, Pfizer and its German partner BioNTech announced that their experimental Covid-19 vaccine was more than 90% effective with no serious safety concerns based on initial trial results. They also estimated that they can roll out up to 50 million doses this year for 25 million people and produce 1.3 billion doses in 2021.
Govt has communicated with 10 Covid-19 vaccine producers, says Khairy KUALA LUMPUR (Nov 16): The government has communicated with 10 Covid-19 vaccine producers following a notification by the World Health Organization (WHO) that there are 11 Covid-19 vaccine candidates in phase 3 clinical trial (as of Nov 13). Science, Technology and Innovation Minister Khairy Jamaluddin said communications with eight of the producers was made directly, while the other two was through the Covid-19 Vaccine Global Access Facility (COVAX). He said some of the discussions are in the final stage and an official announcement would be made when everything has been finalised. “The discussion covers aspects of cooperation in various stages of vaccine development such as R&D (research and development), exchange of scientists, fill and finish development (transfer of technology, logistics, cold chain), including the purchase of vaccines (finished products) as a guarantee of access to vaccine supply for the country," he said during the questions for oral answers session in the Dewan Rakyat today. He was responding to a question from Chan Foong Hin (Pakatan Harapan-Kota Kinabalu) who wanted to know whether the ministry had made any order to import vaccines from companies from China, such as Cansino, Sinovac and Sinopharm, or the UK, such as AstraZeneca, and whether the ministry would set the order of priority for Covid-19 vaccination as being done in Indonesia. Khairy said through participation in COVAX, Malaysia would have access to the supply of Covid-19 vaccine of 10% of the country's population and the government was working to get another 60% to meet the national immunisation target for herd immunity to up to 70 per cent of the country's population. The government, he said, was also working to get vaccine access as early as the first or second quarter of next year depending on the approval from the National Pharmaceutical Regulatory Agency (NPRA). He said the NPRA will ensure that a vaccine passes the stipulated strict conditions, covering its safety and effectiveness through data on the clinical trial that was conducted. Meanwhile, on the list of immunisation priorities, Khairy said the Special Committee on Covid-19 Vaccine Supply Access (JKJAV), set up on Oct 14 , had agreed to divide it into three groups, namely the frontliners, involving staff of the Ministry of Health (MoH) and agencies not under the MoH, such as the police, the Malaysian Armed Forces, Immigration Department and others, in the first group. The second is for high-risk groups, such as individuals with co-morbid and seniors citizens, and the third involves other adult population. Details of the groups are being made and the announcement is expected to be made during the first quarter of next year.
For now... sector rotation. It’s too early for recovery stocks to recover on an unproven news of a vaccine. Based on earnings to come, these stocks will be shit for the next 12 months. Money will flow back after Banks QR. 30-40% uptick in one week is too rich for me. I rather buy the beaten gloves stocks now.
Aiya, all this commenting negative sentiment is waiting to buy cheap la then sell high later. Anyway, news is just vaccine efficacy found on 95 people, not yet approved by WHO and FDA approval for distribution. Also availability of the vaccine for distribution and agreement to supply to all the country. So don't get so carried away tomorrow bloodbath or gap down, price has already factor in Pfizer vaccine news and now it is oversold. So don't have to panic with all the clowns creating negativce excitement.
MODERNA: THIS IS AN INTERIM REPORT FROM 95 PEOPLE We still do not know how long immunity will last as volunteers will have to be followed for much longer before that can be answered. There is also no data on how well it works in older age groups, who are most at risk of dying from Covid. And it is not known whether the vaccine just stops people becoming severely ill, or if it stops them spreading the virus too. All these questions will affect how a coronavirus vaccine is used.
To those who are believing the vaccine hype, don't be fooled by the IBs who are trying hard to make you sell to them. The price is already factored in the Pfizer vaccine news and the shares are oversold. It is not going to go any further down.
Ruth Karron, who heads the Center for Immunization Research at the Johns Hopkins Bloomberg School of Public Health, notes that neither Moderna nor the Pfizer/BioNTech study evaluated whether the vaccine prevented infections as well as symptomatic disease, which is key to controlling the spread of the virus. “The data we have are that these vaccines protect you against severe illness, but it doesn’t mean that you can’t get infected and give it to your patient, your neighbor, your customer, or whomever,” Karron says. But she also says of the Moderna result: “Wow, fantastic, amazing.”
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
drago_7
366 posts
Posted by drago_7 > 2020-11-16 10:21 | Report Abuse
Lau Sai liao..